Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (2028)	7/19/1998 12:29:00 PM
From: ajs	Respond to of 2553

Linda, or anyone else, do think the earnings release, this week will positive and hopefully push us back to 6?

To: Linda Kaplan who wrote (2028)	7/19/1998 6:12:00 PM
From: Bob Jagow	Read Replies (1) \| Respond to of 2553

BW doesn't seem that impressed, Linda, I'd go for AAPL ;) -Bob A knee-repair product called Carticel, approved by the FDA last August, uses somewhat the same principle. Made by Genzyme Tissue Repair, Carticel grows cartilage cells removed from the patient in the lab and then surgically reimplants them in the knee. No matrix is provided, however, so the cells can only be used to repair small rents. To replace the entire meniscus--that's the C-shaped pad in the knee between the thigh bone and shin bone--ReGen Biologics Inc. of Redwood City, Calif., is in clinical trials with a collagen scaffold in the shape of the meniscus. The pad is implanted in the knee to encourage regeneration of the patient's cartilage. Going a step further, Advanced Tissue Sciences is in preclinical trials with a meniscus-shaped cartilage grown in the lab that's meant to work in anyone. It hopes to start human tests by yearend.